February 28, 2017 / 11:45 AM / 7 months ago

Endo Pharma revenue rises 15.6 pct

Feb 28 (Reuters) - Endo International Plc reported a 15.6 percent rise in quarterly revenue on Tuesday, largely driven by demand for its newly launched generic drugs, quetiapine and ezetimibe.

The Dublin, Ireland-based drugmaker’s net loss attributable to shareholders widened to $3.34 billion, or $14.98 per share, in the fourth quarter ended Dec. 31, from $118.46 million, or 53 cents per share, a year earlier.

The company took a $3.5 billion asset impairment charge in the latest quarter, related to its generics reporting unit.

Total revenue rose to $1.24 billion from $1.07 billion.

Quetiapine is an anti-psychotic drug and ezetimibe is used to treat cholesterol.

Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below